-
1
-
-
0028286025
-
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease
-
Kaplan AH, Michael SF, Wehbie RS et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci USA 1994; 91: 5597-601.
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, pp. 5597-5601
-
-
Kaplan, A.H.1
Michael, S.F.2
Wehbie, R.S.3
-
2
-
-
34848844088
-
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study
-
Costagliola D, Descamps D, Assoumou L et al. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 2007; 46: 12-8.
-
(2007)
J Acquir Immune Defic Syndr
, vol.46
, pp. 12-18
-
-
Costagliola, D.1
Descamps, D.2
Assoumou, L.3
-
3
-
-
3142660152
-
The prevalence of antiretroviral drug resistance in the United States
-
Richman DD, Morton SC, Wrin T et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18: 1393-401.
-
(2004)
AIDS
, vol.18
, pp. 1393-1401
-
-
Richman, D.D.1
Morton, S.C.2
Wrin, T.3
-
4
-
-
46349112103
-
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
-
Hirsch MS, Günthard HF, Schapiro JM et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47: 266-85.
-
(2008)
Clin Infect Dis
, vol.47
, pp. 266-285
-
-
Hirsch, M.S.1
Günthard, H.F.2
Schapiro, J.M.3
-
5
-
-
84855616052
-
-
Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. (24 May 2011, date last accessed)
-
Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2011; 1-166. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (24 May 2011, date last accessed).
-
(2011)
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
, pp. 1-166
-
-
-
6
-
-
0037043652
-
Antiretroviral-drug resistance among patients recently infected with HIV
-
Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
-
(2002)
N Engl J Med
, vol.347
, pp. 385-394
-
-
Little, S.J.1
Holte, S.2
Routy, J.P.3
-
7
-
-
40949107410
-
Preexisting resistance to non nucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naïve HIV-1 infected subjects
-
Kuritzkes DR, Lalama CM, Ribaudo HJ et al. Preexisting resistance to non nucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naïve HIV-1 infected subjects. J Infect Dis 2008; 197: 867-70.
-
(2008)
J Infect Dis
, vol.197
, pp. 867-870
-
-
Kuritzkes, D.R.1
Lalama, C.M.2
Ribaudo, H.J.3
-
8
-
-
79955477986
-
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study
-
Wittkop L, Günthard HF, de Wolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-71.
-
(2011)
Lancet Infect Dis
, vol.11
, pp. 363-371
-
-
Wittkop, L.1
Günthard, H.F.2
de Wolf, F.3
-
10
-
-
76449101531
-
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure
-
Paredes R, Lalama CM, Ribaudo HJ et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201: 662-71.
-
(2010)
J Infect Dis
, vol.201
, pp. 662-671
-
-
Paredes, R.1
Lalama, C.M.2
Ribaudo, H.J.3
-
11
-
-
76449107778
-
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients
-
Halvas EK, Wiegand A, Boltz VF et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 2010; 201: 672-80.
-
(2010)
J Infect Dis
, vol.201
, pp. 672-680
-
-
Halvas, E.K.1
Wiegand, A.2
Boltz, V.F.3
-
13
-
-
77955690396
-
Minority variants of drug-resistant HIV
-
Gianella S, Richman DD. Minority variants of drug-resistant HIV. J Infect Dis 2010; 202: 657-66.
-
(2010)
J Infect Dis
, vol.202
, pp. 657-666
-
-
Gianella, S.1
Richman, D.D.2
-
14
-
-
61849172898
-
Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naïve patients significantly impact treatment outcomes
-
Simen BB, Simons JF, Hullsiek KH et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naïve patients significantly impact treatment outcomes. J Infect Dis 2009; 199: 693-701.
-
(2009)
J Infect Dis
, vol.199
, pp. 693-701
-
-
Simen, B.B.1
Simons, J.F.2
Hullsiek, K.H.3
-
15
-
-
70350534553
-
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors
-
Varghese V, Shahriar R, Rhee SY et al. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2009; 52: 309-15.
-
(2009)
J Acquir Immune Defic Syndr
, vol.52
, pp. 309-315
-
-
Varghese, V.1
Shahriar, R.2
Rhee, S.Y.3
-
16
-
-
79952267805
-
Update of the drug resistance mutations in HIV-1: December 2010
-
Johnson VA, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18: 156-63.
-
(2010)
Top HIV Med
, vol.18
, pp. 156-163
-
-
Johnson, V.A.1
Brun-Vézinet, F.2
Clotet, B.3
-
17
-
-
17444388859
-
Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors
-
Harrigan PR, Mo T, Wynhoven B et al. Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2005; 19: 549-54.
-
(2005)
AIDS
, vol.19
, pp. 549-554
-
-
Harrigan, P.R.1
Mo, T.2
Wynhoven, B.3
-
18
-
-
33746216625
-
Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase
-
Berkhout B, Backa NKT, de Rondea A et al. Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase. AIDS 2006; 20: 1515-20.
-
(2006)
AIDS
, vol.20
, pp. 1515-1520
-
-
Berkhout, B.1
Backa, N.K.T.2
de Rondea, A.3
-
19
-
-
62749200513
-
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
-
Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4: e4724.
-
(2009)
PLoS One
, vol.4
-
-
Bennett, D.E.1
Camacho, R.J.2
Otelea, D.3
-
20
-
-
4143099182
-
Identification of the minimal conserved structure of HIV-1 protease in the presence or absence of drug pressure
-
Ceccherini-Silberstein F, Erba F, Gago F et al. Identification of the minimal conserved structure of HIV-1 protease in the presence or absence of drug pressure. AIDS 2004; 18: 11-9.
-
(2004)
AIDS
, vol.18
, pp. 11-19
-
-
Ceccherini-Silberstein, F.1
Erba, F.2
Gago, F.3
-
21
-
-
78650637852
-
on behalf of the 454 HIV Alpha Study Group A multicenter collaborative study on HIV drug resistance testing using 454 massively parallel pyrosequencing
-
Simen BB, Braverman MS, Abbate I et al. on behalf of the 454 HIV Alpha Study Group. A multicenter collaborative study on HIV drug resistance testing using 454 massively parallel pyrosequencing. Antiviral Ther 2010; 15 Suppl 2: A37.
-
(2010)
Antiviral Ther
, vol.15
, Issue.SUPPL 2
-
-
Simen, B.B.1
Braverman, M.S.2
Abbate, I.3
-
22
-
-
77955199812
-
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study
-
Lataillade M, Chiarella J, Yang R et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PLoS One 2010; 3: 5.
-
(2010)
PLoS One
, vol.3
, pp. 5
-
-
Lataillade, M.1
Chiarella, J.2
Yang, R.3
-
23
-
-
34547643929
-
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
-
Wang C, Mitsuya Y, Gharizadeh B et al. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007; 17: 1195-201.
-
(2007)
Genome Res
, vol.17
, pp. 1195-1201
-
-
Wang, C.1
Mitsuya, Y.2
Gharizadeh, B.3
-
24
-
-
77954192930
-
Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution
-
Johnson JA, Geretti AM. Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J Antimicrob Chemother 2010; 65: 1322-6.
-
(2010)
J Antimicrob Chemother
, vol.65
, pp. 1322-1326
-
-
Johnson, J.A.1
Geretti, A.M.2
-
25
-
-
79955002593
-
Selection and co-evolution of mutational patterns in the HIV-1 integrase characterized by pyrosequencing analysis
-
Ceccherini-Silberstein F, Armenia D, D'Arrigo R et al. Selection and co-evolution of mutational patterns in the HIV-1 integrase characterized by pyrosequencing analysis. Antiviral Ther 2009; 14 Suppl 1: A125.
-
(2009)
Antiviral Ther
, vol.14
, Issue.SUPPL. 1
-
-
Ceccherini-Silberstein, F.1
Armenia, D.2
D'Arrigo, R.3
-
26
-
-
48749086685
-
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy
-
Johnson JA, Li JF, Wei X et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 2008; 5: e158.
-
(2008)
PLoS Med
, vol.5
-
-
Johnson, J.A.1
Li, J.F.2
Wei, X.3
-
27
-
-
58749087348
-
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatmentnaïve and -adherent patients
-
Metzner JK, Giulieri SG, Knoepfe SA et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatmentnaïve and -adherent patients. Clin Infect Dis 2009; 48: 239-47.
-
(2009)
Clin Infect Dis
, vol.48
, pp. 239-247
-
-
Metzner, J.K.1
Giulieri, S.G.2
Knoepfe, S.A.3
-
28
-
-
49849095346
-
Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy
-
Peuchant O, Thiébaut R, Capdepont S et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 2008; 22: 1417-23.
-
(2008)
AIDS
, vol.22
, pp. 1417-1423
-
-
Peuchant, O.1
Thiébaut, R.2
Capdepont, S.3
-
29
-
-
80054690981
-
Complex patterns of drug-resistance mutations in newly-diagnosed HIV-infected patients: implications with the transmission of resistant strains
-
Alteri C, Svicher V, Gori C et al. Complex patterns of drug-resistance mutations in newly-diagnosed HIV-infected patients: implications with the transmission of resistant strains. BMC Infect Dis 2009; 1: 11.
-
(2009)
BMC Infect Dis
, vol.1
, pp. 11
-
-
Alteri, C.1
Svicher, V.2
Gori, C.3
-
30
-
-
41449090659
-
Transmission of drug-resistant HIV-1 in Europe remains limited to single classes
-
SPREAD programme
-
SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22: 625-35.
-
(2008)
AIDS
, vol.22
, pp. 625-635
-
-
-
31
-
-
24644472997
-
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
-
Wensing AM, van de Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192: 958-66.
-
(2005)
J Infect Dis
, vol.192
, pp. 958-966
-
-
Wensing, A.M.1
van de Vijver, D.A.2
Angarano, G.3
-
32
-
-
70449723682
-
Transmission of drug-resistant HIV-1 is stabilizing in Europe
-
Vercauteren J, Wensing AM, van de Vijver DA et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200: 1503-8.
-
(2009)
J Infect Dis
, vol.200
, pp. 1503-1508
-
-
Vercauteren, J.1
Wensing, A.M.2
van de Vijver, D.A.3
|